Search results
Results from the WOW.Com Content Network
After sustaining an uptrend on the markets since bottoming in February, GlaxoSmithKline (NYSE:GSK) still has an attractive profile for income and value investors. The stock’s rock-solid dividend ...
GlaxoSmithKline tops the list Continue reading... GlaxoSmithKline tops the list Continue reading... Skip to main content. Subscriptions; Animals ... News. Science & Tech. Shopping. Sports.
With the S&P 500 (SNPINDEX: ^GSPC) yield at just 1.2%, it has become more challenging to find companies or exchange-traded funds (ETFs) that can provide a steady and sizable stream of passive income.
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
The stagnating price paired with dividend raises and the prospect of earnings growth has pushed the share's dividend yield up to 3% and the forward price-to-earnings ratio (P/E) down to just 21.5 ...
In the latest trading session, GlaxoSmithKline (GSK) closed at $41.54, marking a +1.47% move from the previous day.